DrugPatentWatch Database Preview
ASTRAMORPH PF Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which patents cover Astramorph Pf, and when can generic versions of Astramorph Pf launch?
Astramorph Pf is a drug marketed by Fresenius Kabi Usa and is included in four NDAs.
The generic ingredient in ASTRAMORPH PF is morphine sulfate. There are twenty-three drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
US ANDA Litigation and Generic Entry Outlook for Astramorph Pf
A generic version of ASTRAMORPH PF was launched as morphine sulfate by HOSPIRA on December 13th, 2019.
Summary for ASTRAMORPH PF
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 4 |
Bulk Api Vendors: | 17 |
Clinical Trials: | 2 |
Patent Applications: | 7,779 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ASTRAMORPH PF at DailyMed |

Recent Clinical Trials for ASTRAMORPH PF
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Institute on Drug Abuse (NIDA) | N/A |
Vanderbilt University Medical Center | N/A |
National Heart, Lung, and Blood Institute (NHLBI) | Phase 4 |
Synonyms for ASTRAMORPH PF
(-)-(etorphine) |
(-)-Morphine |
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol |
(-)Morphine sulfate |
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraene-10,14-diol |
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0;{1,13}.0;{5,17}.0;{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol |
(1S,5R,13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol |
(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol |
(5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL |
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol |
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol |
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol |
(5alpha,6beta)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol |
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol |
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL |
(Morphine) |
(morphine) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol |
1325730-46-8 |
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol |
2-{4-[2,4-diamino-6-pteridinylmethyl(methyl)amino]phenylcarboxamido}pentanedioic acid(morphine) |
3-(4-Hydroxy-phenyl)-1-propyl-piperidine-3-carboxylic acid ethyl ester |
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol |
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ; HydroChloride |
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ;sulphate salt(morphine) |
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol,sulfate(Morphinesulfate) |
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol((Morphine)) |
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine sulfate) |
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine) |
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)(HCl) |
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diolMorphine |
4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol |
4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (morphine) |
4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine) |
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol |
47106-99-0 |
57-27-2 |
6-tert-Butyl-3-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine |
6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Morphine) |
6211-15-0 (sulfate (2:1) (salt) pentahydrate) |
64-31-3 (sulfate (2:1) (salt) anhydrous) |
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol |
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol |
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol(morphine) |
76I7G6D29C |
8053-16-5 |
85201-37-2 |
863713-90-0 |
9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl- |
9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl- |
Aguettant |
AKOS015966554 |
AN-23579 |
AN-23737 |
Avinza |
BDBM50000092 |
BIDD:GT0147 |
BQJCRHHNABKAKU-KBQPJGBKSA-N |
C01516 |
CCRIS 5762 |
CHEBI:17303 |
CHEMBL3978843 |
CHEMBL70 |
Cube juice |
D-(-)-Morphine |
D08233 |
DB00295 |
DEA No. 9300 |
DepoDur |
Dimorf |
Dinamorf |
Dolcontin |
Dreamer |
DTXSID9023336 |
Dulcontin |
Duramorph |
Duramorph PF |
Duromorph |
EINECS 200-320-2 |
Epimorph |
Epitope ID:116646 |
GTPL1627 |
Hard stuff |
Hocus |
HSDB 2134 |
Infumorph |
Kadian |
l-Morphine |
LS-91748 |
M-Eslon |
M.O.S |
Meconium |
methyl[?]diol |
MOI |
Morfina |
Morfina [Italian] |
Morfina Dosa (TN) |
Morphia |
Morphin |
Morphin [German] |
Morphina |
Morphina [Italian] |
Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl- |
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)- |
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)- |
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)- |
morphine |
Morphine (BAN) |
Morphine [BAN] |
Morphine 0.1 mg/ml in Methanol |
Morphine 1.0 mg/ml in Methanol |
Morphine Anhydrate |
Morphine Extra-Forte |
Morphine Forte |
Morphine H.P |
Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material |
MORPHINE SULFATE |
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE |
Morphine;4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol |
Morphinism |
Morphinum |
Morphitec |
Morphium |
Morpho |
Moscontin |
MS Contin |
Ms Emma |
MS/L |
MS/S |
Mscontin, Oramorph |
MSIR |
Nepenthe |
NSC11441 |
OMS Concentrate |
Oramorph |
Oramorph SR |
Ospalivina |
Rescudose |
RMS |
RMS Uniserts |
Roxanol |
Roxanol 100 |
Roxanol UD |
SCHEMBL2997 |
SDZ 202-250 |
SDZ202-250 |
Sevredol |
Statex Drops |
Statex SR |
Substitol (TN) |
UNII-1M5VY6ITRT component BQJCRHHNABKAKU-KBQPJGBKSA-N |
UNII-76I7G6D29C |
Unkie |
ZINC3812983 |
US Patents and Regulatory Information for ASTRAMORPH PF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | ASTRAMORPH PF | morphine sulfate | INJECTABLE;INJECTION | 071050-001 | Oct 7, 1986 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Fresenius Kabi Usa | ASTRAMORPH PF | morphine sulfate | INJECTABLE;INJECTION | 071053-001 | Oct 7, 1986 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Fresenius Kabi Usa | ASTRAMORPH PF | morphine sulfate | INJECTABLE;INJECTION | 071051-001 | Oct 7, 1986 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Fresenius Kabi Usa | ASTRAMORPH PF | morphine sulfate | INJECTABLE;INJECTION | 071052-001 | Oct 7, 1986 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |